GT Apeiron

Exscientia pays $20M for full control of CDK7 drug, plans breast cancer combo trial
Fierce Biotech
Thu, 07/18/24 - 11:10 am
Exscientia
GT Apeiron
M&A
breast cancer
GTAEXS617